USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ADVANTAGENE, INC
Address:
ADVANTAGENE, INC
440 Lexington St
Auburndale, MA
Phone:
N/A
URL:
N/A
EIN:
522214851
DUNS:
192959851
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,920,771.00 5
SBIR Phase II $9,319,195.00 2

Award List:

Combination of GM-CSF with TKR gene therapy

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Combined gene therapy (Herpes Simplex Virus Thymidine Kinase + Anti-herpetic Prodrug) and radiation therapy (TKR therapy) is a novel approach in the armamentarium against cancer. This radio-gene therapy combination creates a new spatial co-operation whereby two… More

Clinical study of AdV-tk radiogene therapy for glioma

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$758,386.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease with great need of novel therapeutic approaches. Within cancer gene therapy the use of adenoviral vectors to deliver HSV-tk (AdV-tk) has… More

Clinical study of GMCI in Pancreatic Cancer

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$747,384.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Pancreatic adenocarcinoma is the fourth leading cause of cancer deaths in the US; with less than one-year median survival, it accounts for approximately 30,000 diagnoses and deaths per year. Multimodality therapy, including surgery, radiation and chemotherapy,… More

Improved system for producing adenoviral vectors

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$213,871.00
Agency:
HHS
Principal Investigator:
Abstract:
First generation non-replicative adenoviral vectors show promise as anti-cancer agents and as prophylactic vaccines. Current methods for manufacturing these vectors use either the 293 cell line or the PER.C6 cell line. These producer cells provide comple mentary E1a and E1b viral function in the… More

Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$101,130.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The main objective of this project is to develop a new therapeutic to improve the outcome for patients with intermediate-risk prostate cancer. The indication is a first-line adjuvant to be combined with radiation therap y for prostate cancer. The desired outcomes… More

Clinical study of AdV-tk radiogene therapy for malignant glioma

Award Year / Program / Phase:
2007 / SBIR / Phase II
Award Amount:
$2,092,604.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease with great need of novel therapeutic approaches. Within cancer gene therapy the use of adenovira l vectors to deliver HSV-tk (AdV-tk) has… More

Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$7,226,591.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The main objective of this project is to develop a new therapeutic to improve the outcome for patients with intermediate-risk prostate cancer. The indication is a first-line adjuvant to be combined with radiation therap y for prostate cancer. The desired outcomes… More